Tags

Type your tag names separated by a space and hit enter

Prognosis of COVID-19 in patients with breast cancer: A protocol for systematic review and meta-analysis.
Medicine (Baltimore). 2020 Jul 31; 99(31):e21487.M

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) has become a pandemic in the world and posed a great threat to people's health. Several meta-analyses have indicated that many comorbidities were associated with increased risk of COVID-19 severity or mortality. The original report also showed that the mortality rate of COVID-19 in breast cancer patients is more dependent on comorbidities than previous radiation therapy or current anti-cancer therapy. However, no meta-analysis has focused on this aspect. This systematic review aims to assess whether breast cancer will increase the severity and mortality of patients infected with COVID-19 and to explore which factors that may affect the severity or mortality rate of breast cancer patients with COVID-19.

METHODS

We will search the PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), and Wanfang database from December 1, 2019 to June 30, 2020. Cohort studies comparing the disease severity and mortality of COVID-19 patients with and without breast cancer will be included. Two independent reviewers will assess the risk of bias of the included cohort studies using the modified Newcastle-Ottawa Scale. We will conduct meta-analyses to calculate the risk ratio (RR) and 95% confidence interval (95% CI) using the random-effects model with the Mantel-Haenszel method. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach will be used to rate the quality of the evidence.

RESULTS

The results of this study will be published in a peer-reviewed journal.

CONCLUSION

This study will provide comprehensive evidence for medical staff to adopt effective treatment strategies for breast cancer patients during the COVID-19 pandemic.

PROSPERO REGISTRATION NUMBER

CRD42020188208.

Authors+Show Affiliations

Department of Galactophore, Gansu Provincial Cancer Hospital.The Third Ward of Cardiovascular Clinical Medical Center, Affiliated Hospital of Gansu University of Chinese Medicine.The First Clinical Medical College of Lanzhou University.The Second Clinical Medical College of Lanzhou University.The Second Clinical Medical College of Lanzhou University.School of Public Health, Lanzhou University.School of Public Health, Lanzhou University.Rehabilitation Center Hospital of Gansu Province, Lanzhou, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32756178

Citation

Sheng, Zhijuan, et al. "Prognosis of COVID-19 in Patients With Breast Cancer: a Protocol for Systematic Review and Meta-analysis." Medicine, vol. 99, no. 31, 2020, pp. e21487.
Sheng Z, Zhang L, Liu X, et al. Prognosis of COVID-19 in patients with breast cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(31):e21487.
Sheng, Z., Zhang, L., Liu, X., Yuan, L., Li, F., Dai, D., Wu, S., & Yang, J. (2020). Prognosis of COVID-19 in patients with breast cancer: A protocol for systematic review and meta-analysis. Medicine, 99(31), e21487. https://doi.org/10.1097/MD.0000000000021487
Sheng Z, et al. Prognosis of COVID-19 in Patients With Breast Cancer: a Protocol for Systematic Review and Meta-analysis. Medicine (Baltimore). 2020 Jul 31;99(31):e21487. PubMed PMID: 32756178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognosis of COVID-19 in patients with breast cancer: A protocol for systematic review and meta-analysis. AU - Sheng,Zhijuan, AU - Zhang,Li, AU - Liu,Xinlu, AU - Yuan,Li, AU - Li,Fei, AU - Dai,Dingmei, AU - Wu,Shuilin, AU - Yang,Jingzhi, PY - 2020/8/7/entrez PY - 2020/8/7/pubmed PY - 2020/8/25/medline SP - e21487 EP - e21487 JF - Medicine JO - Medicine (Baltimore) VL - 99 IS - 31 N2 - BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a pandemic in the world and posed a great threat to people's health. Several meta-analyses have indicated that many comorbidities were associated with increased risk of COVID-19 severity or mortality. The original report also showed that the mortality rate of COVID-19 in breast cancer patients is more dependent on comorbidities than previous radiation therapy or current anti-cancer therapy. However, no meta-analysis has focused on this aspect. This systematic review aims to assess whether breast cancer will increase the severity and mortality of patients infected with COVID-19 and to explore which factors that may affect the severity or mortality rate of breast cancer patients with COVID-19. METHODS: We will search the PubMed, Embase, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), and Wanfang database from December 1, 2019 to June 30, 2020. Cohort studies comparing the disease severity and mortality of COVID-19 patients with and without breast cancer will be included. Two independent reviewers will assess the risk of bias of the included cohort studies using the modified Newcastle-Ottawa Scale. We will conduct meta-analyses to calculate the risk ratio (RR) and 95% confidence interval (95% CI) using the random-effects model with the Mantel-Haenszel method. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach will be used to rate the quality of the evidence. RESULTS: The results of this study will be published in a peer-reviewed journal. CONCLUSION: This study will provide comprehensive evidence for medical staff to adopt effective treatment strategies for breast cancer patients during the COVID-19 pandemic. PROSPERO REGISTRATION NUMBER: CRD42020188208. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/32756178/Prognosis_of_COVID_19_in_patients_with_breast_cancer:_A_protocol_for_systematic_review_and_meta_analysis_ L2 - https://doi.org/10.1097/MD.0000000000021487 DB - PRIME DP - Unbound Medicine ER -